Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

On Thursday, Aurinia Pharmaceuticals Inc AUPH reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents.The biopharma company reported fourth-quarter sales of $59.9 million, up 33% year over year, almost in line with the consensus of$ 59.9 million.Net product sales of LUPKYNIS, the first FDA-approved oral therapy for active lupus nephritis, were $57.6 million, up 36%.License, collaboration, and royalty revenue, which includes manufactur ...